RxDoctor Payments Data

Kymberly Cullar

Nurse Practitioner · Wichita Falls, TXNPI 1255363800

Payments from drug & device makers

$9,600in general payments, 2019–2025

Across 428 payments — averaging $22.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • AbbVie$1K
  • Johnson & Johnson$1K
  • Neurocrine Biosciences, Inc.$490
  • Alkermes, Inc.$454
  • plus $2K from 17 others

What the payments were for

  • Travel & lodging$5426%
  • Food & beverage$9,01094%
  • Education$470%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,600 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$38,851
Medicare patients
84
Services billed
640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FanaptIloperidone12$39,601
TrintellixVortioxetine Hydrobromide16$11,816
Lurasidone Hcl12$2,945
Bupropion XlBupropion Hcl108$2,358
Alprazolam258$2,291
Aripiprazole42$1,379
Duloxetine Hcl81$1,181
Quetiapine Fumarate49$949
Venlafaxine Hcl ErVenlafaxine Hcl43$749
Trazodone Hcl121$698
Atomoxetine Hcl11$623
Fluoxetine Hcl65$604
Clonazepam65$542
Diazepam40$443
Sertraline Hcl79$341

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Vanda Pharmaceuticals Inc.Fanapt$14$39,60112 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$158$11,81616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Wichita Falls

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →